Know Cancer

forgot password

Paclitaxel Poliglumex (CT-2103) vs. Paclitaxel for the Treatment of Women With Chemotherapy-Naïve Advanced Non-Small Cell Lung Cancer (NSCLC) Who Are Performance Status 2.

Phase 3
18 Years
Not Enrolling

Thank you

Trial Information

Paclitaxel Poliglumex (CT-2103) vs. Paclitaxel for the Treatment of Women With Chemotherapy-Naïve Advanced Non-Small Cell Lung Cancer (NSCLC) Who Are Performance Status 2.

See Summary

Inclusion Criteria:

1. Female.

2. Histologically- or cytologically-confirmed diagnosis of NSCLC.

3. ECOG performance score of 2.

4. Patients who meet one of the following criteria:

- Stage IIIB who are not candidates for combined modality therapy (primary
radiation therapy or surgery), or

- Stage IV.

5. Age greater than or equal to 18 years.

6. Adequate bone marrow function

7. Adequate renal function

8. Adequate hepatic function

9. Patients with known brain metastases must have received standard antitumor treatment
for their CNS metastases as defined by the site’s institutional standards.

10. Patients who have had major surgery must be fully recovered from the surgery.

11. Ability to comply with the visit schedule and assessments required by the protocol.

12. For patients of reproductive potential, commitment to use adequate contraception.

13. Signed approved informed consent, with understanding of study procedures.

14. Agreement to begin study therapy within 8 calendar days after randomization.

Exclusion Criteria:

1. Any intolerance to poly-L-glutamic acid, Poloxamer 188, dibasic sodium phosphate,
monobasic sodium phosphate (the excipients of CT-2103).

2. Evidence of small cell carcinoma, carcinoid, or mixed small cell/non-small cell

3. Any prior systemic chemotherapy for the treatment of lung cancer. This includes
systemic radiosensitizers used to treat brain metastases and any biologic agent.

4. Concurrent primary malignancies except for carcinoma in situ or non-melanoma skin

5. Grade 2 or greater neuropathy.

6. Evidence of significant unstable neurological symptoms within the 4 weeks before
study randomization. (If unstable neurologic symptoms resulted from brain metastases,
patient must meet inclusion criteria number 9).

7. Clinically significant active infection for which active therapy is underway.

8. Investigational therapy within 4 weeks before randomization, unless local
requirements are more stringent.

9. Unstable medical conditions including unstable angina or myocardial infarction within
the past 6 months before randomization. Patients with evidence of cardiac conduction
abnormalities are eligible if their cardiac status is stable.

10. Pregnant women or nursing mothers.

11. Any circumstance at the time of study entry that would preclude completion of the
study or the required follow-up.

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

The primary objective of this study is to compare the overall survival of female patients randomized to CT-2103 to that of female patients randomized to paclitaxel.


United States: Food and Drug Administration

Study ID:




Start Date:

December 2005

Completion Date:

December 2006

Related Keywords:

  • Non-small cell lung cancer
  • PS 2
  • female
  • chemotherapy
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms



West Michigan Cancer Center Kalamazoo, Michigan  49007-3731
SUNY Downstate Medical Center Brooklyn, New York  11203
Hubert H. Humphrey Cancer Center Coon Rapids, Minnesota  55433
Our Lady of Mercy Medical Center Bronx, New York  10466
St. Alexius Medical Center Bismarck, North Dakota  58502
Comprehensive Blood and Cancer Center Bakersfield, California  93309
Pacific Shores Medical Group Long Beach, California  90813
Alamance Cancer Center Burlington, North Carolina  27216
Loma Linda University Cancer Institute Loma Linda, California  92354
Metro Health Medical Center Cleveland, Ohio  44109
Mary Crowley Medical Research Center Dallas, Texas  75246
Genesis Cancer Center Hot Springs, Arkansas  71913
Bond Clinic Rolla, Missouri  65401
Saint Louis University St. Louis, Missouri  63104
Oncology Care Associates, PLLC Saint Joseph, Michigan  49085
Medical Oncology Care Associates Orange, California  92668
Tower Cancer Research Foundation Beverly Hills, California  90211
Flint, Michigan  48532
Broward Oncology Associates Ft. Lauderdale, Florida  33308
Providence St. Joseph Medical Center Burbank, California  91505
The Cleveland Clinic Foundation, Taussig Cancer Center Cleveland, Ohio  44195
Charleston Hematology Oncology Charleston, South Carolina  29403
Dayton Clinical Oncology Program Dayton, Ohio  45420
Kentucky Cancer Clinic Pikeville, Kentucky  41501
Montana Cancer Specialists Missoula, Montana  59807-7877
Cabrini Center for Cancer Care Alexandria, Louisiana  71301
Northern Indiana Cancer Research Consortium South Bend, Indiana  
Cancer & Blood Disease Center Lecanto, Florida  34461
The Family Cancer Center Collierville, Tennessee  38017
Heritage Physician Group, Oncology Hot Springs, Arkansas  71913
Northwestern Carolina Oncology & Hematology Hickory, North Carolina  28601
Desert Oasis Cancer Center Casa Grande, Arizona  85222
Signal Point Hematology/Oncology, Inc. Middletown, Ohio  45042
JPS Center for Cancer Care Fort Worth, Texas  76104
Sierra Nevada Oncology Care Carson City, Nevada  89703
Interlakes Foundation, Inc. Rochester, New York  14623
West Kentucky Hematology & Oncology Group, PSC Paducah, Kentucky  42003
Arizona Hematology Oncology Tucson, Arizona  85704
Pacific Cancer Medical Center, Inc Anaheim, California  92801
Hematology/Oncology Group of Fresno, Inc Fresno, California  93720
Comprehensive Cancer Center-Research Office Glendale, California  91204
The Cancer Research and Prevention Center Soquel, California  95073
Bethesda Research Center Boynton Beach, Florida  33435
Florida Wellcare Inverness, Florida  34452
Oncology-Hematology Associates of West Broward Tamarac, Florida  33321
Hematology Oncology Speaclist Tampa, Florida  33607
Joliet Oncology Hematology Associates, Ltd. Joliet, Illinois  60435
Loyola University Health Systems Maywood, Illinois  60153
Mid-Illinois HEM & ONC Assoc. Normal, Illinois  61761
Associated Physicians & Surgeons Clinic Terre Haute, Indiana  47804
St. Louis Cancer Care Center Chesterfield, Missouri  63017
Columbia Comprehensive Cancer Care Clinics Columbia, Missouri  65201
Washington University Siteman Cancer Center Pharmacy St. Louis, Missouri  63110
Essex Oncology of North Jersey, PA Belleville, New Jersey  07109
Atlanta HEM ONC Manasquan, New Jersey  08736
Oncology and Hematology Specialist, PA Moutain Lakes, New Jersey  07046
San Juan Oncology Association Farmington, New Mexico  87401
Cancer Treatment Services Corning, New York  14830
Guthrie Clinic Sayre, New York  18840
New York Medical Collegw Valhalla, New York  10595
UNC Chapel Hill Oncology Protocol Office Chapel Hill, North Carolina  27599
Leo Jenkins Cancer Center Greenville, North Carolina  28734
University of Cleveland Cleveland, Ohio  44106
Columbia Basin HEM/ONC Kennewick, Washington  99336